On Mar. 11, 2021, ContraFect announced that it had been awarded a cost-share contract from the Biomedical Advanced Research and Development Authority (BARDA). The Company was to receive $9.8 million in initial funding and up to an additional $77.0 million.

The initial funding supported ContraFect’s pivotal Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) superiority study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.

Under the terms of the agreement, and if supported by Phase 3 DISRUPT study data, BARDA provided the Company with additional funding upon achievement of key milestones to continue the advancement of exebacase through U.S. Food and Drug Administration product approval and completion of post-approval commitments.